The linked FDA records identify Med-El Corp. as the applicant on P000025, with a filing address in Innsbruck, Austria. The original approval covers the COMBI 40+ Cochlear Implant System, described in the approval order as intended to provide the opportunity to detect and recognize auditory information through electrical stimulation of the auditory nerve. Later supplements address manufacturing and labeling changes rather than new device categories. [2][4][1]

Original approval and device scope

P000025 was approved on August 20, 2001, with the trade name COMBI 40+ COCHLEAR IMPLANT SYSTEM and generic name Implant, cochlear. The approval statement describes electrical stimulation of the auditory nerve for severely to profoundly hearing-impaired individuals who obtain little or no benefit from conventional acoustic amplification in the best-aided condition. The advisory committee is listed as Ear, Nose, Throat. [2]

A later summary document states that the original P000025 for the MED-EL Cochlear Implant System was approved on August 20, 2001, and that the original device was intended to provide the opportunity to detect and recognize auditory information. That document also lists the applicant as MED-EL Corp., Elektromedizinsiche Geraete GmbH, at the same Innsbruck address. [4]

Supplement activity

Supplement S136, a 30-day notice review track filing received June 5, 2025 and decided October 9, 2026, carries the trade name MED-EL Cochlear Implant System. Its approval statement covers expanding the shelf-life of a raw material used for making the overmold of the MED-EL cochlear implants, under supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. [1]

Supplement S134 is documented in a Summary of Safety and Effectiveness Data with an FDA notice of approval dated November 26, 2025, again naming MED-EL Elektromedizinische Geräte GmbH in Innsbruck as applicant. That summary describes a planned study of cochlear implantation in children aged 7 months to 18 years, conducted as a prospective/retrospective, non-controlled, non-randomized, multicenter study at 8 sites. [7]

Supplement S129 carries a Summary of Safety and Effectiveness Data with an FDA notice of approval dated October 3, 2024, listing the same applicant name and address and the device trade name MED-EL Cochlear Implant System. The PMA index page for P000025 notes that the device has supplements and that the description, function or indication may have changed, so the labeling shown reflects the version at the time of approval. [4][5]

How to read the filing record

The supplied collection contains two linked PMA records, both with an approval decision, and the record sample shows the same two entries: the 2001 original approval and the 2026 S136 supplement. These counts describe the supplied filings as of the snapshot date and are not a measure of total company portfolio, sales or safety performance. [1][2]

FDA pages for P000025 and its supplements state that a supplement may have changed the device description, function or indication from that approved in the original PMA. The applicant name on these filings is Med-El Corp.; the records do not establish a parent company, brand structure or headquarters beyond the filing address shown. [3][5]